Book contents
- Dispatches from the Land of Alzheimer’s
- Reviews
- Dispatches from the Land of Alzheimer’s
- Copyright page
- Dedication
- Lost in Thought
- Contents
- Acknowledgments
- Prologue
- 1 Physician Heal Thyself
- 2 Evaluating New Advances in Alzheimer’s Research
- 3 Alzheimer’s Dementia or Alzheimer’s Disease
- 4 The First Patient with Alzheimer’s Disease
- 5 Kidnapped in Kinshasa
- 6 Smell, Disgust, and Alzheimer’s
- 7 Apolipoprotein-4 (APOE-4)
- 8 Lost in the Fog of Alzheimer’s
- 9 My Father’s “Stuff”
- 10 Face Blindness during a Pandemic
- 11 Biomarkers for Alzheimer’s Disease
- 12 Olfactory Impairment in Covid-19 and Alzheimer’s
- 13 Alzheimer’s Disease and Work
- 14 Crossword Controversies
- 15 Can Loneliness Increase Risk for Dementia?
- 16 Excessive Laxative Use and Dementia
- 17 Dog Dementia (Canine Cognitive Dysfunction)
- 18 The Possible Role of Brain Inflammation in Alzheimer’s Disease May Be More Significant in APOE-4 Carriers
- 19 Surprisingly Good News about the Acetylcholinesterase Inhibitors (Donepezil, Rivastigmine, and Galantamine)
- 20 More about the Importance of Exercise
- 21 Rolling on the River
- 22 The MIND Diet Revisited
- 23 My Photographs, Then and Now
- 24 Does Cataract Surgery Really Decrease the Risk of Dementia?
- 25 Hearing Loss, Aphasia, and Dementia
- 26 To Sleep, Perchance to Dream
- 27 The Amyloid Hypothesis Is Not Dead, but It May Be Gasping for Breath
- 28 Could Lecanemab Offer a Ray of Hope?
- 29 A Fatal Case of Multiple Brain Hemorrhages Associated with Lecanemab
- 30 Cerebral Amyloid Angiopathy (CAA)
- 31 Hitting the Sweet Spot in the Spectrum of Alzheimer’s Disease for Future Trials of Anti-Amyloid Medications
- 32 Disappointing Results of Two Human Trials of Monoclonal Antibodies in Parkinson’s Disease
- 33 Repurposing Old Drugs for Alzheimer’s Treatment
- 34 Writing While Impaired
- 35 Spreading the Word
- 36 Saying Goodbye to Lizzie G
- 37 Amyloid and Tau PET Scans of My Brain
- 38 Running on a Field of Dreams
- 39 Living in the Moment with Alzheimer’s
- Index
- Plate Section (PDF Only)
- References
3 - Alzheimer’s Dementia or Alzheimer’s Disease
What’s the Difference and Why Should We Care?
Published online by Cambridge University Press: 19 January 2024
Book contents
- Dispatches from the Land of Alzheimer’s
- Reviews
- Dispatches from the Land of Alzheimer’s
- Copyright page
- Dedication
- Lost in Thought
- Contents
- Acknowledgments
- Prologue
- 1 Physician Heal Thyself
- 2 Evaluating New Advances in Alzheimer’s Research
- 3 Alzheimer’s Dementia or Alzheimer’s Disease
- 4 The First Patient with Alzheimer’s Disease
- 5 Kidnapped in Kinshasa
- 6 Smell, Disgust, and Alzheimer’s
- 7 Apolipoprotein-4 (APOE-4)
- 8 Lost in the Fog of Alzheimer’s
- 9 My Father’s “Stuff”
- 10 Face Blindness during a Pandemic
- 11 Biomarkers for Alzheimer’s Disease
- 12 Olfactory Impairment in Covid-19 and Alzheimer’s
- 13 Alzheimer’s Disease and Work
- 14 Crossword Controversies
- 15 Can Loneliness Increase Risk for Dementia?
- 16 Excessive Laxative Use and Dementia
- 17 Dog Dementia (Canine Cognitive Dysfunction)
- 18 The Possible Role of Brain Inflammation in Alzheimer’s Disease May Be More Significant in APOE-4 Carriers
- 19 Surprisingly Good News about the Acetylcholinesterase Inhibitors (Donepezil, Rivastigmine, and Galantamine)
- 20 More about the Importance of Exercise
- 21 Rolling on the River
- 22 The MIND Diet Revisited
- 23 My Photographs, Then and Now
- 24 Does Cataract Surgery Really Decrease the Risk of Dementia?
- 25 Hearing Loss, Aphasia, and Dementia
- 26 To Sleep, Perchance to Dream
- 27 The Amyloid Hypothesis Is Not Dead, but It May Be Gasping for Breath
- 28 Could Lecanemab Offer a Ray of Hope?
- 29 A Fatal Case of Multiple Brain Hemorrhages Associated with Lecanemab
- 30 Cerebral Amyloid Angiopathy (CAA)
- 31 Hitting the Sweet Spot in the Spectrum of Alzheimer’s Disease for Future Trials of Anti-Amyloid Medications
- 32 Disappointing Results of Two Human Trials of Monoclonal Antibodies in Parkinson’s Disease
- 33 Repurposing Old Drugs for Alzheimer’s Treatment
- 34 Writing While Impaired
- 35 Spreading the Word
- 36 Saying Goodbye to Lizzie G
- 37 Amyloid and Tau PET Scans of My Brain
- 38 Running on a Field of Dreams
- 39 Living in the Moment with Alzheimer’s
- Index
- Plate Section (PDF Only)
- References
Summary
I now have a special interest in Alzheimer’s disease. For nearly 25 years, I practiced general neurology in Portland, Oregon. Some of my patients had dementia, a progressive neurological disorder that causes severe cognitive impairment affecting memory, language, motivation, and mood, interfering with everyday activities. There are several diseases that can cause dementia, including Lewy body disease, Parkinson’s disease, frontotemporal degeneration, and vascular dementia, but Alzheimer’s disease is the most common cause, accounting for 60–80% of cases. In 2013, I retired because I had developed mild cognitive impairment (MCI) that was soon shown by biomarker testing to be due to early-stage Alzheimer’s disease. I suddenly wore two hats – that of a retired physician with a lot of experience treating Alzheimer’s disease and now a person living with the same disorder.
Keywords
- Type
- Chapter
- Information
- Dispatches from the Land of Alzheimer's , pp. 12 - 17Publisher: Cambridge University PressPrint publication year: 2024
References
Gibbs, DM. Early awareness of Alzheimer disease: A neurologist’s personal perspective. JAMA Neurology 2019; 76: 249. https://doi.org/10.1001/jamaneurol.2018.4910. PMID: 30776065.CrossRefGoogle ScholarPubMed
Honig, LS, Vellas, B, Woodward, M, et al. Trial of solanezumab for mild dementia due to Alzheimer’s disease. N Engl J Med 2018; 378: 321–330. https://doi.org/10.1056/NEJMoa1705971. PMID: 29365294.CrossRefGoogle ScholarPubMed
Clinical trial of solanezumab for older individuals who may be at risk for memory loss (A4). https://clinicaltrials.gov/ct2/show/NCT02008357 (accessed May 12, 2022).Google Scholar
A donanemab (LY3002813) prevention study in participants with Alzheimer’s disease (TRAILBLAZER-ALZ 3). https://clinicaltrials.gov/ct2/show/NCT05026866 (accessed May 12, 2022).Google Scholar
A study to evaluate the efficacy and safety of gantenerumab in participants at risk for or at the earliest stages of Alzheimer’s disease (AD) (SKYLINE). https://clinicaltrials.gov/ct2/show/NCT05256134 (accessed May 12, 2022).Google Scholar
van Dyck, CH, Swanson, CJ, Aisen, P, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med 2023; 388: 9–21. https://doi.org/10.1056/NEJMoa2212948.CrossRefGoogle ScholarPubMed
AHEAD 3-45 Study: A study to evaluate efficacy and safety of treatment with lecanemab in participants with preclinical Alzheimer’s disease and elevated amyloid and also in participants with early preclinical Alzheimer’s disease and intermediate amyloid. https://clinicaltrials.gov/ct2/show/NCT04468659 (accessed December 29, 2022).Google Scholar
2023 Alzheimer’s Disease Facts and Figures. www.alz.org/media/documents/alzheimers-facts-and-figures.pdf, pages 20–22 (accessed March 27, 2023, open access).Google Scholar
Brookmeyer, R, Abdalla, N, Kawas, CH, Corrada, MM. Forecasting the prevalence of preclinical and clinical Alzheimer’s disease in the United States. Alzheimers Dement 2019; 14: 121–129. www.ncbi.nlm.nih.gov/pmc/articles/PMC5803316/ (accessed December 17, 2022, open access).CrossRefGoogle Scholar